Understanding daily life with facioscapulohumeral muscular dystrophy
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This study explores how facioscapulohumeral muscular dystrophy (FSHD) affects your daily life, health, and living situation. It does not test a new treatment, but aims to better understand the challenges patients face.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with facioscapulohumeral muscular dystrophy (FSHD).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing an investigational drug, SRP-1001, to see if it helps people with facioscapulohumeral muscular dystrophy type 1 (FSHD1), a condition that causes muscle weakness. The study will check if the drug is safe and if it can slow down the loss of muscle function.
This study creates a patient-driven health and research platform for people with FSHD. It aims to collect information to better understand the condition and improve future research and care.
This study looks at how children with FSHD move and function over time. It uses walking tests and optional MRI scans to understand muscle changes. Your child's participation could help researchers learn more about FSHD progression in kids.
This study looks at how walking changes over time in people with facioscapulohumeral muscular dystrophy (FSHD). It aims to understand walking patterns to help improve future care.
This trial studies how well certain physical/movement tests work in people with facioscapulohumeral muscular dystrophy (FSHD). It may help clinicians measure changes more accurately and tailor care over time.
This registry aims to collect health information from people in the UK who have facioscapulohumeral muscular dystrophy (FSHD). It helps researchers better understand the disease and plan future studies.
Hear when a new Muscular Dystrophy, Facioscapulohumeral trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.